Lori A. Schretzman

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor

Jeffery A. Zablocki, Masateru Miyano, Robert B. Garland et al. · Journal of Medicinal Chemistry · 1993 · 107 citations

Pharmaceutical Science, Pharmacotherapy, Rgdx Mimetics +21

Potent in Vitro and in Vivo Inhibitors of Platelet Aggregation Based Upon the Arg-Gly-Asp Sequence of Fibrinogen. (Aminobenzamidino)succinyl (ABAS) Series of Orally Active Fibrinogen Receptor Antagonists

Jeffery A. Zablocki, Joseph G. Rico, Robert B. Garland et al. · Journal of Medicinal Chemistry · 1995 · 104 citations · Full text

Pharmacotherapy, Platelet Aggregation, Molecular Pharmacology +21

Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture

Norman Abood, Lori A. Schretzman, Daniel L. Flynn et al. · Bioorganic & Medicinal Chemistry Letters · 1997 · 48 citations

Neurovirology, Antiviral Activity, Immunology +10

Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective αvβ3 receptor antagonists

Mark L. Boys, Lori A. Schretzman, Nizal S. Chandrakumar et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 47 citations · Full text

Engineering, Medicine, Drug Discovery +7

A novel series of orally active antiplatelet agents

Jeffery A. Zablocki, Foe S. Tjoeng, Philippe R. Bovy et al. · Bioorganic & Medicinal Chemistry · 1995 · 32 citations

Thrombopoiesis, Thrombosis, Platelet Aggregation Inhibitors +7